Onco Actu du 29 septembre 2016

	2. Etiologie
Tattoo ink contains cancer-causing chemicals – so why isn't it regulated? [The Guardian] “Just because something can cause cancer doesn’t mean that it does,” she said. “As far as I know there have not been any studies convincingly or conclusively linking tattoo pigment to an increased risk for cancer.”
	4. Dépistage, diagnostic et pronostic
High-tech scan after chemotherapy could indicate whether head and neck cancer treatment is working [The Institute of Cancer Research] Their study, published in The Journal of Nuclear Medicine, is the first in head and neck squamous cell carcinoma to compare PET/CT and MRI scans following each cycle of chemotherapy.
	5. Traitements
Is every disease a rare disease? [STAT] Just because we understand the mechanism of a disease, doesn’t mean that we can find a drug for it. And that’s one of the real challenges of precision medicine.
	5.10 Traitements - Essais
80% of Chinese clinical trials' data fabricated [PharmaFile] Though the extent of the scandal may be surprising, there has long been an awareness of issues within China’s pharmaceutical practises. Third party agencies that are tasked with inspecting facilities, known as contract research organisation, are quoted by the report as being “accomplices in data fabrication due to cutthroat competition and economic motivation”.
	5.12 Immunothérapies
On the Horizon of Cancer: The Future of Immunotherapy [Kantar Health] Kantar Health’s newly developed CancerLandscapeTM platform identifies 23 immune checkpoint-targeted therapies in 893 trials in development, including 12 immune costimulators in 41 trials.
CICON16: Bacteria and Cancer Immunity [CRI] In addition to chemotherapy, bacteria can also improve immunotherapy responses. Zitvogel showed that, for CTLA-4 blockade therapy to work against CRC, sarcoma, and melanoma in mice, gut bacteria are required.
	5.12.1 Immunothérapies - partenariats
bluebird bio and Medigene Establish Strategic T Cell Receptor (TCR) Alliance in Cancer Immunotherapy [bluebird bio] T cell receptor (TCR) therapeutic candidates against four targets to be generated using Medigene’s proprietary TCR technology platform and bluebird bio’s lentiviral vector, genome editing, synthetic biology, and manufacturing capabilities.
	5.12.3 Immunothérapies-combinaisons
Incyte’s IDO1 update on its Keytruda combo scores some positive reviews [EndPoints] Incyte’s latest cut on the data from a Phase I/II study of its combination therapy adding Merck’s checkpoint star Keytruda to its closely watched IDO1 enzyme inhibitor epacadostat for melanoma is continuing to impress observers. And that is all boding well for a newly launched Phase III study.
	5.2 Pharma
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution [FiercePharma] “They only analyzed the studies that didn’t include the prevention,” Auerbach said. “Because of that, yes, there’s a high rate of diarrhea. When you use the Imodium, the rates come down dramatically and it completely changes the safety and tolerability profile of the drug.”
Why big pharma wants to collect 2 million genomes [Nature] For the head of AstraZeneca’s genomics initiative, the challenge is not just getting the sequences, but in putting them to use — wisely.
	5.2.1 Pharma - Partenariats
Boehringer Ingelheim Boosts Immune-Oncology Pipeline through Collaboration with VitaTherapeutics [Boehringer Ingelheim] New long-term collaboration to develop next generation oncolytic virus platform and lead candidate VSV-GP.
Gearing up new partnerships, Boehringer gets an option to buy a new player in oncolytic viruses in $230M deal [EndPoints] After backing a small startup round for ViraTherapeutics a little more than a year ago, the pharma company has come back with a $230 million package deal to partner on their work — grabbing an option in the process to buy the company.
	5.3 Traitements - FDA, EMA,...
Is the FDA Too Cozy With Drug Companies? [Time] Critics have called out this revolving door between the FDA and the pharmaceutical industry, and the study’s authors wanted to see how the numbers matched up to that claim.
EU-US collaboration to boost medicine development for rare diseases [ESMO] The European Medicines Agency (EMA) announced that EMA and the US Food and Drug Administration (FDA) have set up a new ‘ cluster’ on rare diseases to share experiences and best practices on each other’s regulatory approach to the development of medicines for these diseases.
	5.4 Traitements - Economie
Most Americans believe prescription drug prices are unreasonable [STAT] The survey also found that 86 percent of Americans believe drug makers should be required to disclose data used to set prices.
	5.6 ESMO
Clovis Oncology Announces Rucaparib Data Presentations at ESMO 2016 Congress [Clovis Oncology] Rucaparib is the Company’s oral, potent, small molecule inhibitor of PARP1, PARP2 and PARP3 currently being developed for the treatment of advanced ovarian cancer, specifically in patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA (commonly referred to as homologous recombination deficiencies, or HRD).
Two New Trials of Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016 [Merck] Results from KEYNOTE-024, which Studied KEYTRUDA Compared to Chemotherapy in Patients with High Levels of PD-L1 Expression, and KEYNOTE-021G, which Studied KEYTRUDA in Combination with Chemotherapy Compared to Chemotherapy Alone in Patients Regardless of PD-L1 Expression, to be Presented.
Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress [Pfizer] The presentations demonstrate progress addressing cancer’s complex challenges through our work across 11 tumor types and eight distinct mechanisms of action, including two immuno-oncology/targeted therapy combination studies in renal cell carcinoma (RCC).
ESMO 2016 Poster Abstracts Published Online Today [ESMO] This year, the total of submitted abstracts was 2,884 (regular and late breaking) of which 1,640 were accepted.
	6. Lutte contre les cancers
NCI collaborates with Multiple Myeloma Research Foundation [NIH] The foundation will donate important data to the NCI Genomic Data Commons.
	6.10 Politiques
Science spending boosted in French budget [Nature] Mandon tells Nature that he expects the success rate of grant applications to the agency to rise from 9% last year to 14% this year, and up to 20% next year.
	6.10.1 Politiques (USA)
ASCO Calls on Congress to Fund Cancer Moonshot Initiative [ASCO] ASCO has been an active participant in the Cancer Moonshot Initiative, and continues to provide recommendations and feedback to Vice President Joe Biden, the Blue Ribbon Panel, and the Task Force on concrete steps for accelerating the prevention, diagnosis, and treatment of cancer.
	6.3 Associations/Fondations
What some stories missed about the muscular dystrophy drug approval: Pharma’s close ties to vocal patient advocacy groups [HealthNewsReview] Following the money in any news story is important, but the relationship between advocacy organizations and their pharmaceutical backers often receives less attention than it should.
	6.6 Publications
Old Media, New Media, Data Media: Evolving Publishing Paradigms [Scholarly Kitchen] Into this debate about Old and New steps a new candidate, the model of the data science company, which neither creates content (the prerogative of the Old) nor aims to serve as a platform for third-party content (the aim of the New).
	6.9 Controverses
Flawed Research Tool Leads To Faulty Medical Findings [NPR] In one iconic case, a multi-million dollar effort to produce a test to guide treatment for melanoma fell apart, after the researcher conducting the cancer study discovered that his antibodies were utterly unreliable.
Despite the Hype Over Gene Therapy, Few Drugs Are Close to Approval [MIT Technology Review] Most experts in the medical field will tell you that gene therapy has finally come of age, but the numbers tell a different story. Despite 30 years of research and a bigger pipeline than ever, only a small number of gene therapy trials have completed late-stage testing or are currently in late-stage trials.